NEWS
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are NOT in the Best Interests of the Company and its Shareholders
On June 19, 2024, Vanda Pharmaceuticals (Nasdaq: VNDA) announced its Board of Directors REJECTED unsolicited takeover proposals from Cycle Group Holdings and Future Pak The offers were $8.00 per share in cash from Cycle Group and $8.50-$9.00 per share in cash plus Contingent Value Rights (CVRs) from Future Pak. The Board determined these proposals undervalue Vanda, citing their clinical development pipeline, commercial presence, and significant cash balance. They deemed the CVRs speculative due to uncertain commercial milestones under Future Pak's management. Vanda remains confident in its long-term growth and value creation potential.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
950Followers
63Following
6415Visitors
Follow
Zam Kasim : Add to my WL . Thanks